Organogenesis (ORGO) Projected to Post Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is anticipated to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Organogenesis to post earnings of ($0.29) per share and revenue of $43.2620 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%.The company had revenue of $225.61 million during the quarter, compared to the consensus estimate of $172.68 million.

Organogenesis Price Performance

NASDAQ ORGO opened at $2.56 on Wednesday. The company has a current ratio of 3.62, a quick ratio of 3.32 and a debt-to-equity ratio of 0.04. Organogenesis has a 12 month low of $2.21 and a 12 month high of $7.08. The stock has a market cap of $328.78 million, a price-to-earnings ratio of 31.89 and a beta of 1.31. The company’s 50 day moving average is $2.62 and its two-hundred day moving average is $3.91.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of Organogenesis in a research report on Thursday, March 26th. Weiss Ratings raised Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, February 27th. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a research note on Sunday, March 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Insiders Place Their Bets

In other Organogenesis news, Director Michael Joseph Driscoll purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average price of $2.67 per share, with a total value of $26,700.00. Following the completion of the purchase, the director directly owned 225,707 shares in the company, valued at $602,637.69. This trade represents a 4.64% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new stake in Organogenesis during the first quarter valued at approximately $105,000. Creative Planning lifted its position in Organogenesis by 84.5% in the second quarter. Creative Planning now owns 35,392 shares of the company’s stock worth $130,000 after buying an additional 16,205 shares during the last quarter. Cetera Investment Advisers purchased a new position in Organogenesis during the second quarter worth $222,000. American Century Companies Inc. increased its position in Organogenesis by 25.6% during the second quarter. American Century Companies Inc. now owns 164,793 shares of the company’s stock valued at $603,000 after acquiring an additional 33,573 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Organogenesis by 36.6% in the second quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company’s stock valued at $617,000 after acquiring an additional 45,021 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.